Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Prospective, Open-Label, Single-Arm Study of Homoharringtonine Combined With Lisaftoclax and Azacitidine in Patients With Acute Myeloid Leukemia After Failure of Venetoclax-Based Therapy

NCT07813390 is registered in ClinicalTrials.gov with Guangdong Second Provincial General Hospital as lead sponsor.

NCT NCT07813390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07813390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Prospective, Open-Label, Single-Arm Study of Homoharringtonine Combined With Lisaftoclax and Azacitidine in Patients With Acute Myeloid Leukemia After Failure of Venetoclax-Based Therapy
Lead sponsor
Guangdong Second Provincial General Hospital
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
September 1, 2026
Completion date
August 31, 2028
Enrollment
73 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)